MoonLake Immunotherapeutics MLTX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

AnaptysBio, Inc.ANAB

——

Nektar TherapeuticsNKTR

——

Kymera TherapeuticsKYMR

——

Arcutis Biotherapeutics, Inc.ARQT

——

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is MoonLake Immunotherapeutics's available for sale securities debt securities current?: MoonLake Immunotherapeutics (MLTX) reported available for sale securities debt securities current of $59.43M in Q1 2026.
How has MoonLake Immunotherapeutics's available for sale securities debt securities current changed year-over-year?: MoonLake Immunotherapeutics's available for sale securities debt securities current decreased by 71.5% year-over-year, from $208.56M to $59.43M.